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1ABSTRACT
The effect of P-glycoprotein on the brain uptake of [18F]Mefway in 
rodents
Jin Chung
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Young Hoon Ryu)
I. INTRODUCTION
Efflux transporters in brain capillary endothelial cells impede xenobiotics, 
including therapeutic drugs and PET radioligands. Of these, P-gp 
(P-glycoprotein) and Bcrp (Breast cancer resistance protein) are prominent 
efflux pumps. P-gp is colocalized with Bcrp on the luminal membranes of brain 
capillary endothelial cells, and they have partly overlapping substrate 
specificities that include a wide range of compounds. Thus, to investigate the 
effects of P-gp, it is required to evaluate the impact of Bcrp. The aim of this 
study was to determine whether the brain uptake of [18F]Mefway is influenced 
by the action of P-gp and Bcrp in rodents. 
II. MATERIALS AND METHODS
To effectively suppress in vivo defluorination, fluconazole (OneFlu, JW 
Pharmaceutial, Seoul, Korea) was used. [18F]Mefway was applied to the 
pharmacological inhibition rats and genetically disrupted mice. In rats, blocking 
of P-gp activity was performed by tariquidar (TQD). For the pharmacological 
inhibition experiments male Sprague-Dawley (n = 3 for each group) rats were 
2used. For genetic disruption, male Mdr1a/b(-/-), Bcrp1(-/-), Mdr1a/b(-/-)Bcrp1(-/-), 
and wild-type (WT) mice were used (n = 4 for each group).
III. RESULTS
Pretreatment of TQD results in 160% higher hippocampal uptake compared 
with control rats. In genetically disrupted mice, a maximal brain uptake value of 
3.2 SUV in the triple knockout mice (Mdr1a/b(-/-)Bcrp1(-/-) was comparable to 
that of the double knockout mice (Mdr1a/b(-/-)) and two-fold those of the wild 
type and Bcrp1(-/-) knockout mice. The differences of binding values were 
statistically insignificant between control and experimental groups. The 
brain-to-plasma ratios for triple knockout mice were also 2-5 times higher than 
those for other groups. 
IV. CONCLUSION
In PET, chemical knockout P-gp disruption induced considerable increase 
of brain uptake of [18F]Mefway compared with control group or wild 
type. This result was substantiated by ex vivo experiments showing high 
brain-to-plasma ratios for P-gp disrupted mice. In conclusion, [18F]Mefway 
is modulated by P-gp, and not by Bcrp in rodents.
----------------------------------------------------------------------------------------
Key words : [18F]Mefway, P-glycoprotein, Breast cancer resistance protein, 
PET
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I. INTRODUCTION
Multiple lines of evidence suggest that disturbance of serotonin 1A 
(5-HT1A) receptors in the central nervous system is closely related to the 
etiology of various psychiatric disorders.1 Assessment of integrity of 5-HT1A
receptors is therefore an important subject in neuroscience. 
Drug transporters belonging to the adenosine triphosphate binding 
cassette (ABC) family present in various tissues and play an important role in 
drug absorption and distribution.2 Particularly, efflux transporters in brain 
capillary endothelial cells impede xenobiotics, including therapeutic drugs and 
PET radioligands.3,4 Of these, P-glycoprotein (P-gp) and breast camcer 
resistance protein (Bcrp) are prominent efflux pumps. P-gp is colocalized with 
Bcrp on the luminal membranes of brain capillary endothelial cells,5 and they 
have partly overlapping substrate specificities that include a wide range of 
compounds.6,7 Thus, to investigate the effects of P-gp, it is required to evaluate 
the impact of Bcrp. 
If one radiotracer is an avid substrate for these efflux transporters, the 
transporters work to limit the brain accessibility of that radiotracer and provide 
4poor imaging signals. In this situation, reduced brain uptake results in either a 
small number of available receptors or active transporter function. Moreover, 
transporter activity has been described to change in neurologic diseases such as 
epilepsy and Alzheimer's disease.8,9 This makes quantification of receptor 
binding more difficult if the radiotracer is a transporter substrate. Therefore, the 
evaluation of the effect of efflux transporters on the brain uptake of radiotracers 
is considered to be an important subject.  
Positron emission tomography (PET) can non-invasively detect the 
receptor density in the plasma membrane due to its high sensitivity of 10-9 ~ 
10-12 M.10 The majority of radioligands for quantification of 5-HT1A receptors 
have been developed from N-{2-[4-(2-methoxyphenyl)piperazinyl]ethyl}-N-2-
Pyridylcyclohexanecarboxamide (WAY-100635). Although [carbonyl-11C]
WAY-100635, trans-4-18F fluoro-N-2-[4-(2-methoxyphenyl)piperazin-
1-yl]ethyl]-N-(2-pyridyl)cyclohexanecarboxamide([18F]FCWAY)
and 4-18F-fluoranyl-N-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-
N-pyridin-2-ylbenzamide ([18F]MPPF) have been applied to human subjects, 
these radiotracers had some limitations such as fast metabolism, metabolic 
instability and low penetration to the brain.11-13 Later, [18F]Mefway, which has 
comparably high selectivity and affinity to 5-HT1A receptors and in vivo
metabolic stability against radiodefluorination in humans, was developed to 
overcome these difficulties. Its efficacy in subjects ranging from rodents to 
humans has been previously demonstrated.14-23
In terms of permeability to drug transporters in the blood brain barrier 
(BBB), small chemical structure changes can induce a profound impact the 
susceptibility to brain efflux.24 While [carbonyl-11C]WAY-100635 was a weak 
5P-gp substrate, benzyl substituted ([18F]-MPPF) and  reversed amide group 
analogue ([11C]-(R)-RWAY) were identified as strong P-gp substrates.25-27
Although [18F]MPPF is identified as a strong P-gp substrate for rodent BBB, 
this seems not to be the case for primate BBB.28 [18F]Mefway is a WAY-100635 
derivative and has an enlarged alkyl group compared to [18F]FCWAY. Thus we 
assumed that [18F]Mefway PET images could also be influenced by P-gp 
function. The purpose of the present study is to investigate the possible 
influence on P-gp on the brain uptake of [18F]Mefway by pharmacological and 
genetically modulation of P-gp.
II. MATERIALS AND METHODS
1. General
All chemicals and solvents were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). [18F]fluoride ion was produced in the medical cyclotron 
(Eclipse HP, Siemens Ltd., Knoxville, TN, USA). Radioactivity was counted in 
a Capintec CRC-15R dose calibrator. Thin-layer chromatography was 
performed in Bioscan (Washington DC, USA). The crude product was purified 
by a high performance chromatograph (YL9100, Young Lin Instrument Co., Ltd, 
Anyang, Korea) with a reverse column (Xterra Prep, RP 18, 10 mm x 250 mm, 
Waters, Milford, MA, USA). To effectively suppress in vivo defluorination, 
fluconazole (OneFlu, JW Pharmaceutial, Seoul, Korea) was used. Tariquidar 
(TQD, MedKoo Bioscience , Chapel Hill, NC, USA) for injection was dissolved 
in propylene glycol, DMSO, and 5% dextrose solution (4:5:1) and immediately 
administrated to the rat.  PET acquisition was carried out in an Inveon PET 
scanner (Siemens, Knoxville, TN, USA) This scanner has a peak absolute 
6system sensitivity of ≥10 % in the 250–750 keV energy window, an axial field 
of view of 12 cm, 1.4-mm full width at half maximum (FWHM) spatial 
resolution at the center of the field of view, and a transaxial field of view of 10 
cm. The PET images were analyzed with commercial software (PMOD, 3.1, 
PMOD Technologies Ltd., Adliswil, Switzerland). The chromatographic 
separation was performed with an Agilent (Palo Alto, CA) 1200 series HPLC 
system equipped with a Gemini C18 analytical column (50 × 2.0 mm, 3 μm i.d.; 
Phenomenex, Torrance, CA, USA) at a flow rate of 0.3 mL/min for 1.8 min. 
The MS/MS analysis was conducted using a tandem quadrupole mass 
spectrometer (Agilent 6460A, Palo Alto, CA).
2. Animals
For the pharmacological inhibition experiments male Sprague-Dawley 
(Raon Bio. Inc. Yong-in, Korea, body weight: 260 - 300 g, n = 3 for each 
group) rats were used. For genetic disruption, male Mdr1a/b(-/-)
(FVB.129P2-Abcb1atm1BorAbcb1btm1Bor, Bcrp1(-/-) (FVB.129P2-Abcg2tm1Ahs), 
Mdr1a/b(-/-)Bcrp1(-/-) (FVB.129P2-Abcb1atm1BorAbcb1btm1BorAbcg2tm1Ahs), and 
wild-type (WT) mice with FVB genetic background were obtained from 
Taconic Inc. (Germantown, NY, USA, body weight: 24 -30 g, n = 4 for each 
group). Mdr1a/b(-/-) knockout was created through sequential targeting of 
Abcb1a and Abcb1b in E14 embryonic stem cells (ES) cells. Resultant chimeras 
were backcrossed to FVB/N for seven generations (N7). Bcrp1(-/-) was created 
by targeting Abcg2 in E14 ES cells derived from 129P2/OlaHsd mice and 
injecting the targeted cells into FVB blastocysts. Resultant chimeras were 
backcrossed to FVB/N for N7. Mdr1a/b(-/-)Bcrp1(-/-) was created through the 
7crossbreeding of the Mdr1a/b targeted-mutation mouse and the Bcrp 
targeted-mutation mouse.
Animals were housed in a temperature- and humidity-controlled room 
with a 12-h light/dark cycle and had free access to food and water. All animal 
studies were approved by the Committee for the Care and Use of Laboratory 
Animals at Yonsei University College of Medicine. All applicable institutional 
guidelines for the care and use of animals were followed. 
3. Radiochemistry
[18F]Mefway was synthesized by nucleophilic substitution reaction of 
p-tosylated precursor as previously described.29 Specific activity at the end of 
synthesis was higher than 90 GBq/µmol as assessed by high performance liquid 
chromatography and radiochemical purity exceeded over 99 %. 
4. Acquisition of PET Images
Animals were anesthetized with 2.5% isoflurane and catheters were 
inserted into the tail veins. Fluconazole (60 mg/kg) was infused at a constant 
rate to the veins of rats and mice for 1 h to suppress in vivo defluorination.29 The 
body temperature was maintained at 36oC using the heating mat. The head of 
animal was placed in center of PET gantry. For rats, TQD (6 mg/kg) was 
bolusly injected to inhibit P-gp activity, followed by administration of 
radioactivity at a rate 1mL/min (12.4 ± 2.8 MBq). The PET response was the 
highest at this TQD dose, which is in good correspondence with previous 
findings.30 For mice, radioactivity was injected solely to the tail at a rate 
5ml/min (12.4 ± 2.8 MBq). PET images were acquired in the list mode for 90 
8min (mice) or 120 (rats), then attenuation corrections were performed for only 
rat using data from a 10-min transmission scan with a 57Co point source. 
5. Image Analysis
Raw PET data were reconstructed in user-defined time frames (10 sec 
× 6 frames, 30 sec × 8 frames, 300 sec × 5 frames, 1800 sec × 2 frames for mice, 
10 sec × 6 frames, 30 sec × 8 frames, 300 sec × 5 frames, 1800 sec × 3 frames 
for rats) with voxel dimensions of 0.86 × 0.86 × 0.80 mm3 by a 2-dimensional 
order-subset expectation maximization (OSEM) algorithm. The acquired images 
were evaluated by region-of-interests (ROIs) analysis using PMOD 3.1. 
Regions of interests are the hippocampus and cerebellum. The cerebellum was 
used as reference tissue for kinetic modeling because this region is known to 
have very low concentration of 5-HT1A receptors in rodents. Time-activity 
curves (TACs) in these regions were acquired and regional TACs were 
normalized in units of standardized uptake value (SUV). 
Individual binding value estimations were computed from multilinear 
reference tissue model (MRTM).31 Then with these estimated k2’s, regional 
distribution volume ratios (DVR) were calculated by using the non-invasive 
Logan’s graphical analysis method.32 Estimated non-displaceable binding 
potentials (BPND) were calculated as DVR - 1.  
6. Ex Vivo Quantification of Mefway
After completion of PET, the mice were awakened from anesthesia and 
returned to their cage until the ex vivo quantification of Mefway. Animals were 
intravenously administered cold Mefway at 5 mg/kg. After 1h, the mice were 
9euthanized, and the blood and brain were collected immediately. After washing, 
the tissues were added to five volumes of phosphate buffered saline per weight, 
homogenized, and stored at –20°C until analyzed for Mefway by LC-MS/MS.
The concentration of cold Mefway was determined by a LC-MS/MS method 
developed in our laboratory. Briefly, 30-µL plasma samples were mixed with 
270-µL of acetonitrile–methanol mixed solution (1:1, v/v) containing 20 ng/mL 
of the internal standard (IS), gliclazide and centrifuged (15,800g, 10 min). The 
clear supernatants were transferred to LC-MS/MS vials, and then a 5-μL aliquot 
was injected into the LC-MS/MS system. Multiple reaction monitoring modes 
were used for the quantification: m/z 455.3 → 263.1 for Mefway and m/z 324.1 
→ 110.1 for gliclazide (internal standard). The fragmentor energy of the MS 
was set at 155 and 115V for Mefway and gliclazide, respectively. The peak 
areas of all samples were integrated automatically using MassHunter program 
(Agilent Inc.).
7. Statistical Analysis
All data are presented as mean ± standard error of the mean (SEM). 
Differences in BPND values were analyzed with the student t-test. All statistical 
analyses were performed with Prism 5 (ver. 5.04, GraphPad, La Jolla, CA, 
USA). 
III. RESULTS
1. Pharmacological inhibition of P-gp 
Representative PET summation images in the rat brain showed that 
pharmacological inhibition of P-gp using TQD resulted in apparent increment of 
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brain radioactivity (Fig. 1). 
Figure 1. Representative PET images in the rat brain. Control group (A) and 
phamacologogical inhibition group (B). Shown are time-averaged images from 
the brain between 0 - 90 min. Cross indicates the hippocampus. 
In the control rats, hippocampal and the cerebellar uptakes peaked 
early (> 5 min) and were 3.6 SUV and 2.1 SUV in control rats, respectively. In 
the P-gp blocked rats, radioactivities in the hippocampus and the cerebellum 
were 2.2- and 3.9-fold those of the control group, respectively
(Fig. 2). 
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Figure 2. Regional time-activity curves before and after administration of 
tariquidar (TQD). Red line means TQD pretreated group and black line shows 
the control group. Data represent mean ± standard error of the mean (SEM).
Quantitative analysis using the non-invasive Logan's graphical method resulted 
in comparable mean values for the BPND (control group: 3.13 vs. TQD 
pretreatment = 3.46, respectively, Table 1). 
Table 1.  BPND values in the rats and the mice
Rat Mice
Control
P-gp 
inhibition
Wild type Bcrp(-/-) Mdr1a/b(-/-)
Mdr1a/b(-/-)
Bcrp(-/-)
3.13 ± 0.29 3.46 ± 0.35 1.64 ± 0.14 1.65 ± 0.17 1.83 ± 0.26 1.73 ± 0.31
Data are presented as mean ± SD
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The difference of binding values was not statistically significant. The kinetic 
analysis resulted in comparable mean values for the BPND in the P-gp and/or 
Bcrp disrupted mice: (BPND values: Mdr1a/b
(-/-) = 1.83 , Mdr1a/b (-/-)/Bcrp1(-/-) =
1.73, Bcrp1(-/-) = 1.65, and WT = 1.64, respectively, Table 1).
2. Genetically disrupted mice
As shown in Fig. 3A, genetically P-gp disrupted mice (i.e., Mdr1a/b(-/-)
and Mdr1a/b(-/-)Bcrp1(-/-) showed considerably higher brain uptakes compared 
with WT or Bcrp1(-/-). The highest hippocampal uptake was observed in 
Mdr1a/b(-/-)Bcrp(-/-) mice and these uptake values were not statistically different 
from Mdr1a/b(-/-). Peak uptake values for Mdr1a/b(-/-) and Mdr1a/b(-/-)Bcrp(-/-)
were about 1.7-fold those in the WT and Bcrp1(-/-) mice (p < 0.001) whereas, the 
uptake differences between Bcrp1(-/-) and WT were insignificant (p = 0.62, Fig. 
3B). 
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Figure 3. Coronal PET summation and peak uptake values at 10 min in the 
transgenic mice. (A) Coronal PET summation images (0 - 60 min) of wild-type, 
Bcrp1(-/-), Mdr1a/b(-/-), and Mdr1a/b(-/-)Bcrp1(-/-). (B) Peak uptake values at 10 
min in the transgenic mice (n= 3). Mean bars indicate the significant differences 
of the hippocampal uptake between Mdr1a/b(-/-)Bcrp1(-/-) or Mdr1a/b(-/-) and 
wild-type (***P <0.001). However, there was no significant difference between 
Bcrp1(-/-) and wild-type (p = 0.62). Data represent mean ± standard error of the 
mean (SEM).
The kinetic analysis resulted in comparable mean values for the BPND in the 
P-gp and/or Bcrp disrupted mice: (BPND values: Mdr1a/b(-/-) = 1.83, Mdr1a/b 
(-/-)/Bcrp1(-/-) = 1.73, Bcrp1(-/-) = 1.65, and WT = 1.64, respectively, Table 1).
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3. Brain-to-plasma ratio of Mefway
The brain-to-plasma ratios of P-gp disrupted groups were significantly 
higher than those in the WT and Bcrp1(-/-) groups (p = 0.048 for Mdr1a/b(-/-) and 
p < 0.001 Mdr1a/b(-/-)Bcrp(-/-) compared with WT, Fig. 4). 
15
Figure 4. Comparison of Mefway concentration in plasma (A), brain (B), and 
brain-to-plasma ratio (C). Mean bars indicate the significant differences in the 
Mdr1a/b(-/-) (*p = 0.048) or in the Mdr1a/b(-/-)Bcrp1(-.-) (***P < 0.001) compared 
with wild-type. Data represent mean ± standard error of the mean (SEM). 
The substantially higher ratio in Mdr1a/b(-/-)Bcrp1(-/-) mice compared to 
Mdr1a/b(-/-) was likely caused by the widespread distribution of P-gp in tissues 
other than the brain including the intestine, liver, and kidneys .
IV. DISCUSSION
In the present study, we evaluated the effect of efflux transporters on 
the brain uptake of [18F]Mefway in the rodent brain. After pharmacological 
modulation of P-gp activity, radioactivities in the brain was significantly 
elevated compared with the control group. In the genetic inhibition model, P-gp 
knockout groups also showed higher brain uptake value than Bcrp knockouts or 
wild type. These results are in accordance with ex vivo experiments showing 
16
the high brain concentration in P-gp knockout mice. Taken together, our results 
suggest, for the first time to our knowledge, that [18F]Mefway is a P-gp 
substrate, not Bcrp in the murine BBB. 
To investigate the effects of P-gp on the brain uptake of [18F]Mefway, 
we performed PET studies using different rodent models: chemical inhibition 
and genetic knockout systems. For chemically knocked out rats, we used 
tariquidar as a P-gp specific modulator because this intravenous administration 
of TQD in rats induces fast and long inhibition of P-gp in the absence of 
interaction with cytochrome P450 activity.33 The first- and second- generation 
P-gp inhibitors such as verapamil, cyclosporine A, valspodar have low 
selectivity and binding affinity to P-gp.34 However, the pharmacological 
blockade of P-gp using TQD induces inhibits Bcrp activity.35 Hence, we used 
genetic inhibition mice. In the present study, the highest brain uptake value in 
P-gp/Bcrp knockout mice can be accounted for by synergistic effects. PET 
results were quite in opposition to an in vitro bidirectional transport assay 
showing that 18F-Mefway was not a substrate for P-gp (data not shown). This 
discrepancy could be explained in that an in vitro bidirectional transport assay is 
not appropriate for drugs that quickly permeate cell monolayers.36
To evaluate the differences of binding potential, we used non-invasive 
Logan's graphical analysis. Compartment modeling with the arterial input 
function is considered as the gold standard in neuroreceptor PET analysis 
generating the ratio of tracer concentration between plasma and the brain in the 
equilibrium state. However, this method is highly influence by the action of 
P-gp. Before a substrate completely crosses the BBB, a P-gp efflux pump 
transports some extent of its substrate from the endothelial membrane to the 
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plasma. This P-gp action causes either increased efflux from or decreased 
transport to the brain.26 Moreover, the plasma concentration of the substrate is 
often affected by this efflux pump.37 On the other hand, the reference model is 
much less sensitive to P-gp activity. In the present study, the differences of 
BPND values between the control and experiment groups were comparable. 
These results imply that P-gp function is similar in both the receptor rich and 
poor region. This P-gp activity agrees that comparable binding values in the 
striatum and the cerebellum for [18F]Fallypride in rodents.38
The fact that [18F]Mefway is a P-gp substrate in rodents is likely 
indicative of similar characteristics in higher species, but further investigation is 
required. Species differences in TQD induced P-gp modulation exists. In fact, 
several radioligands such as [11C]verapamil, [11C]flumazenil, [11C](R)-RWAY, 
and [18F]altanserin known as P-gp substrates in rats have displayed sufficient 
brain uptake in humans.39 Uchida et al. suggested that different degrees of 
uptake in primates compared to rodents are strongly influenced by differences 
in transporter expression at the BBB.40 Based on these perspectives, 
[18F]Mefway may not be affected by P-gp in higher species. From only genetic 
disruption PET results, we cannot absolutely exclude effect of Bcrp on the brain 
uptake of [18F]Mefway. Further studies are needed to assess this issue.
Although this study is lack of radiochromatographic and plasma protein 
binding analysis, we think that these issues are not critical for evaluation of 
P-gp on the brain uptake for [18F]Mefway. The previous work demonstrated that 
[18F]-trans-4-fluoromethylcyclohexane carboxylate as a major metabolite of 
[18F]Mefway was extensively localized in peripheral regions.20 In addition, if 
majority of a TQD is bound to rodent plasma proteins and plasma free fraction 
18
of [18F]Mefway is large, the enhancement of brain uptake can be attributed to 
the effect of TQD. However, this hypothesis are unlikely because a plasma free 
fraction of [18F]Mefway was quantified of 5 % or 15 % in monkeys and 5 % in 
humans, respectively.17,41 Genetically disrupted mice also showed the increment 
of brain uptakes in the P-gp knockout mice. 
Even if [18F]Mefway is a substrate for P-gp in the rodent brain, this 
radioligand may be a candidate for clinical studies. Firstly, [18F]Mefway showed 
less susceptibility to Bcrp activity. In humans, Bcrp was expressed at the BBB 
significantly more highly than P-gp based on mRNA and proteomic 
analysis.40,42 Moreover, [18F]Mefway has a higher target-to-reference value than 
[18F]MPPF and considerably greater metabolic stability against 
radiodefluorination than [18F]FCWAY in humans.14,17,43,44
V. CONCLUSION
In [18F]Mefway PET, chemical knockout P-gp disruption induced 
considerable increment of brain uptakes compared with control group or wild
type. This result was substantiated by ex vivo experiments showing high
brain-to-plasma ratios for P-gp disrupted mice. These studies demonstrated that
[18F]Mefway is a substrate for P-gp in rodent brain.
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ABSTRACT(IN KOREAN)
설치류의 [18F]Mefway에서 뇌 섭취에 기여하는
P-glycoprotein의 효과
<지도교수 유영훈>
연세대학교 대학원 의학과
정진
I. 목적
뇌 모세혈관 내피 세포에서 유출 운반자들은 치료 약물들과 PET
방사성 리간드들을 포함한 생체이물질들을 방해한다. 이들 중에서
P-glycoprotein (P-gp)와 breast cancer resistance protein (Bcrp)는 가장
중요한 유출 운반자들이다. P-gp는 뇌 모세혈관 내피 세포의
관강내막에 Bcrp와 함께 발현이 되어 있으며 일부 기질 특이성을
공유하고 있다. 따라서 P-gp의 효과를 알아보기 위해서는 Bcrp의
효과를 알아볼 필요성이 있다. 본 연구의 목적은 설치류의
[18F]Mefway에서 P-glycoprotein (P-gp)와 breast cancer resistance protein 
(Bcrp)의 뇌섭취에 관련된 효과를 알아보고자 하였다.
II. 대상 및 방법
탈불소화를 효과적으로 억제시키기 위하여 fluconazole (OneFlu, JW 
Pharmaceutial, 서울, 대한민국)를 사용하였다. [18F]Mefway를
약물학적으로 억제시킨 쥐와 유전적으로 변형시킨 생쥐에게 적용을
하였다. 쥐에서는 tariquidar(TQD)를 이용하여 P-gp 기능을 억제
시켰다. 약물학적으로 억제시키는 실험을 위해서는 수컷
Sprague-Dawley (각 그룹 당 세 마리) 쥐를 사용하였다. 유전적 변형을
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위하여서는 수컷 Mdr1a/b(-/-), Bcrp1(-/-), Mdr1a/b(-/-)Bcrp1(-/-), 그리고 대조군
생쥐가 사용되었다 (각 그룹 당 네 마리). 
III. 결과
TQD를 전처치함으로써 대조군 쥐와 비교 시 해마의 뇌 섭취가 160%
증가되었다. 유전적으로 변형된 생쥐에서, 최대 뇌 섭취가 3.2 SUV인
삼중 유전자 결손 생쥐 (tKO, Mdr1a/b(-/-)Bcrp1(-/-) 와 비교 시 이중
유전자 결손 생쥐 (dKO, Mdr1a/b(-/-)) 와 최대 뇌 섭취가
비슷하였으며 대조 군과 Bcrp1(-/-) 유전자 결손 생쥐와 비교 시 두 배
높은 최대 뇌 섭취를 보였다. 대조 군과 실험 군간의 결합 가치의
차이는 통계적으로 의미가 없는 것으로 나타났다. [18F]Mefway
농도의 뇌와 혈장간 비율은 다른 그룹과 비교 시 삼중 유전자 결손
생쥐에서 2.5배 높은 것으로 확인되었다. 
IV. 결론
PET에서 화학적으로 P-gp 결여된 경우 대조군과 비교시
[18F]Mefway의 뇌에서 섭취도가 매우 많이 증가되었다. 이러한
결과는 P-gp 결손 생쥐에서도 높은 뇌-혈장간 비율을 보인 실험
결과에서도 입증되었다. 결론적으로 [18F]Mefway는 설치류에서
Bcrp가 아닌 P-gp에 의해서 조절이 된다.
----------------------------------------------------------------------------------------
핵심되는 말 : [18F]Mefway, P-glycoprotein, 유방암 저항성 단백질
(Breast cancer resistance protein), 양전자 단층촬영 (PET)
